The revival of vaginal surgery in the era of endoscopy: V-NOTES initial experience with a series of 32 patients.

Background: Transvaginal natural orifice transluminal endoscopic surgery (V-NOTES) is an emerging surgical technique in the evolution of minimally invasive surgery. This technique allows different types of surgical procedures to be performed by vaginal access with endoscopic control. The combination of vaginal surgery and laparoscopy brings many advantages, especially the absence of incisions in the abdominal wall and better visualization of the abdominal cavity. Objectives: In this retrospective study we report our initial experience of V-NOTES in benign gynaecologic surgery by describing our first consecutive 32 surgeries. Materials and Methods: From June 2020 to January 2022, 32 gynaecological procedures were performed by V-NOTES by the same surgeon in a university hospital. Perioperative outcomes were evaluated retrospectively. Main outcome measures: Conversion to laparoscopy or laparotomy and peri-operative and post-operative complications. Results: None of the 32 V-NOTES procedures required conversion to conventional laparoscopy or laparotomy. We observed 2 intraoperative complications managed by V-NOTES and 2 post-operative complications (Clavien-Dindo Grade 2). Conclusion: Our results are similar to studies previously published about this subject and are promising concerning the techniques efficacy and safety. We do believe that a short training allows to reach benefits safely. However, further prospective multicentre randomized trials comparing V-NOTES to totally laparoscopic hysterectomy and to vaginal hysterectomy are needed to strengthen the validity of this new approach. What's new?: V-NOTES widens the indications of vaginal hysterectomies by removing limitations such as large uterus, absence of prolapse, and history of caesarean. Moreover, this technique allows adnexal surgery to be performed by vaginal access.

[An update in intrauterine contraception]. / Nouveautés en contraception intra-utérine.

Intrauterine devices (IUD) are the oldest of the modern contraceptives. There are currently two types of IUDs: copper IUD (Cu-IUD) and levonorgestrel IUD (LNG-IUD). Both offer high contraceptive effectiveness. Although they have been used for decades, the literature still brings its share of new information on IUDs: impact on oncological risk, non-contraceptive benefits, rare adverse effects, and impact on women's well-being. In addition, Cu-DIU is recognized as the most effective emergency contraceptive and can be inserted up to 5-7 days after the at-risk sexual intercourse. Research is now looking at the effectiveness of LNG-IUD in emergency contraception. Finally, new IUD concepts are also being evaluated: they should allow a reduction in the rate of expulsion, intermenstrual and heavy menstrual bleeding, an increase in comfort and in IUDs duration of use. This article makes an update on the latest developments in terms of intrauterine contraceptives.

Le dispositif intra-utérin (DIU) est le plus ancien des contraceptifs modernes. On distingue les DIU au cuivre (Cu-DIU) et les DIU au lévonorgestrel (LNG-DIU). Ils offrent une haute efficacité contraceptive. Bien qu'ils soient utilisés depuis des décennies, la littérature apporte encore aujourd'hui son lot de nouvelles informations sur les DIU: impact sur le risque oncologique, bénéfices non contraceptifs, effets indésirables rares et impact sur le bien-être des femmes. Par ailleurs, le Cu-DIU est reconnu comme étant le contraceptif d'urgence le plus efficace, pouvant être inséré jusqu'à 5-7 jours après le rapport à risque. La recherche se penche maintenant sur l'efficacité du LNG-DIU en contraception d'urgence. Enfin, de nouveaux concepts de DIU sont aussi à l'étude : ils devraient permettre une réduction du taux d'expulsion, une diminution des méno- et métrorragies, une augmentation du confort et une plus longue durée d'utilisation. Cet article fait le point sur les dernières nouveautés en termes de contraceptifs intra-utérins.

[Endometriosis as an inflammatory disease ?] / L'endométriose est-elle une pathologie inflammatoire ?

Endometriosis is the presence of stromal and epithelial cells outside the uterine cavity. This chronic inflammatory disease affects about 10 % of the female population in reproductive age and is responsible for chronic pelvic pain and infertility. Its pathogenesis is complex, and the treatment will rely on medical treatment or/and surgery. Medical treatment consists in alleviating pain thanks to analgesic and hormonal treatment but none can eradicate the disease. Medical treatment often fails and about 10 % will add nonsteroid anti-inflammatory drugs to their hormonal treatment. Major role of immune/inflammatory cells in the disease makes them a promising tool for targeted therapy.

: L'endométriose est définie par la présence de cellules stromales et épithéliales endométriales en dehors de la cavité utérine. Considérée comme une pathologie inflammatoire chronique, elle touche environ 10 % des femmes en âge de procréer et est responsable de douleur pelvienne et d'infertilité. Sa pathologie est complexe et le traitement sera médical et/ou chirurgical. Le traitement médical consistera à soulager la douleur grâce à des antalgiques et une hormonothérapie, mais aucune des molécules utilisées actuellement ne permet l'éradication de l'endométriose. Le traitement médical échoue fréquemment. Il est estimé que 10 % des patientes ne seront pas soulagées par une hormonothérapie seule et nécessiteront le recours à des anti-inflammatoires. Le rôle prépondérant des cellules et cytokines inflammatoires dans la survenue de la maladie permet d'envisager des thérapies ciblées.

[Uterine rupture in a patient with a cesarean scar pregnancy]. / Cas clinique. Rupture utérine en début de grossesse sur cicatrice de césarienne.

Caesarean scar pregnancy is a rare form of ectopic pregnancy, but it is increasingly common due to the increasing number of caesarean sections and advances in medical imaging. There are two types of cesarean scar pregnancy depending on the depth of the implantation : endogenous type I and exogenous type II. In the case of a pregnancy resulting from a type II caesarean scar, the main complication is uterine rupture, which could be life-threatening for the patient. Early diagnosis and treatment are therefore essential for the woman. We report the case of a patient in early pregnancy with a history of cesarean section who presented with severe pelvic pain due to uterine rupture.

La grossesse sur cicatrice de césarienne est une forme rare de grossesse extra-utérine mais dont la fréquence augmente en raison du nombre croissant de césariennes et du progrès de l'imagerie médicale. Il en existe deux types en fonction de la profondeur d'implantation : le type I endogène et le type II exogène. Dans les cas d'une grossesse sur cicatrice de césarienne de type II, la complication principale est la rupture utérine qui pourrait engager le pronostic vital de la patiente. Un diagnostic et un traitement précoce sont donc primordiaux pour la patiente. Nous rapportons le cas d'une patiente en début de grossesse avec un antécédent de césarienne qui se présente pour des douleurs abdominales aiguës dues à une rupture utérine.

[Third- and fourth-degree post-delivery perineal tears : retrospective analysis and management adaptation]. / Les déchirures périnéales des 3ème et 4ème degrés post-accouchement : analyse rétrospective et adaptation de la prise en charge.

Third- and fourth-degree perineal tears are injuries involving the anal sphincter that occur during vaginal delivery. Their prevalence is between 0.25 and 6 %, which highlights the variability of obstetrical practice among different countries. This type of tear can lead to short- and long-term complications for the mothers, affecting their quality of life. Therefore, it seems essential that their management should be optimal. In this study, we analyzed the records of all women who suffered from an obstetric anal sphincter injury between January 2015 and January 2021. During this period, out of 11222 vaginal deliveries, 61 records (0.54%) were retained. Maternal, fetal, and delivery-related risk factors were studied and were mostly similar to those found in the literature. However, the treatment of these lesions was very heterogeneous among patients and lacked standardization. A better management of these tears through the establishment of a decision algorithm would potentially reduce the long-term morbidity.

Les déchirures périnéales des troisième et quatrième degrés sont des lésions entreprenant le sphincter anal et survenant lors de l'accouchement par voie vaginale. Leur prévalence est comprise entre 0,25 et 6 %, ce qui souligne la variabilité de la pratique obstétricale selon les pays. Ce type de lésion peut entraîner des complications à court et long termes pour les patientes, affectant leur qualité de vie. Dès lors, il semble essentiel que leur prise en charge soit optimale. Dans cette étude rétrospective monocentrique, les dossiers des femmes ayant présenté une lésion obstétricale du sphincter anal entre janvier 2015 et janvier 2021 ont été analysés. Durant cette période, sur 11.222 accouchements par voie basse, 61 dossiers (0,54 %) ont été retenus. Les facteurs de risque maternels, fœtaux et liés à l'accouchement ont été étudiés et sont majoritairement similaires à ceux retrouvés dans la littérature. En revanche, la prise en charge de ces lésions était très hétérogène parmi les patientes, avec un manque de standardisation. Une meilleure gestion de ces déchirures via l'instauration d'un algorithme décisionnel permettrait potentiellement d'en diminuer la morbidité à long terme.

[Should you operate on a uterine septum ?] / Faut-il opérer un septum utérin ?

Uterine septum is the most common congenital uterine malformation and may cause obstetric problems such as repeated miscarriages, premature deliveries or dystocial presentations. It also appears to be associated with infertility. The uterine septum can be demonstrated by ultrasound, MRI and hysteroscopy. The benefit of hysteroscopic septoplasty remains controversial although most studies agree on the benefits of this treatment. It improves the fertility and obstetrical future of women by increasing the rate of pregnancies and live births and reducing the rate of miscarriages. Resection of the uterine septum is therefore encouraged in symptomatic patients but also in prophylaxis, in asymptomatic patients in order to increase the chances of carrying their pregnancy to term.

Le septum utérin est la malformation utérine congénitale la plus fréquente et peut être à l'origine de problèmes obstétricaux tels que des fausses couches à répétition, des accouchements prématurés ou des présentations dystociques. Par ailleurs, il semble également associé à une infertilité. Le septum utérin peut être mis en évidence à l'aide de l'échographie, de l'IRM et de l'hystéroscopie. Le bénéfice d'une septoplastie hystéroscopique reste controversé bien que la plupart des études s'accordent sur les bienfaits de ce traitement. En effet, il permet d'améliorer la fertilité et l'avenir obstétrical des patientes en augmentant le taux de grossesses et de naissances d'enfants vivants et en réduisant le taux de fausses couches. La résection du septum utérin est donc encouragée chez les patientes symptomatiques, mais également, en prophylaxie, chez des patientes asymptomatiques afin d'augmenter les chances de mener leur grossesse à terme.

Daily practice management of septate uterus: reproductive outcome after septoplasty.

Background: Septate uterus is the most common uterine malformation found in women presenting poor reproductive history. Hysteroscopic septoplasty (HS) restores the uterine anatomy in a safe procedure. Objectives: The goal of our study is to determine the reproductive outcomes after HS of symptomatic septate uterus. Materials and Methods: In a retrospective observational single centre study the reproductive outcomes and complications after HS were evaluated in 31 women with symptomatic septate uterus. The patients were separated into two groups according to the symptoms - infertility or recurrent pregnancy loss (RPL). Main outcome measures: were the pregnancy and live birth rate and secondarily the complication rate. Furthermore, the results were analysed depending on the need of assisted reproductive techniques (ART). Results: The treatment has resulted in an overall pregnancy rate of 71% for both groups. The spontaneous pregnancy rate is 45% and 8 pregnancies resulted from ART (26%). The overall first live birth rate is 51.6%. A decrease has been noticed in the miscarriage rate from 95.24% to 24% (p<0.001) in the overall population. Conclusions: In patients with a symptomatic septate uterus hysteroscopic septoplasty is a safe and effective procedure. The favourable results pointing out the benefits of surgery on the reproductive outcomes as well as the relatively simple and safe technique of HS make the intervention attractive.

[Oocyte cryopreservation : medical and social indications]. / La cryoconservation d'ovocytes : indications médicales et sociétales.

The increasing survival rate in cancer patients and the global tendency to delay motherhood are two distinct phenomena leading to an increased demand for fertility preservation. Currently, fertility preservation is possible to be achieved with less hormonal exposure and without delaying oncological treatments. Based on this knowledge, any patient with an oncological diagnosis should be referred to a fertility specialist to consider gamete cryopreservation. In addition, the indication for fertility preservation have been extended to many benign pathologies. Awareness of age-related fertility decline coupled with a tendency to delay motherhood is leading more and more women to consider social egg freezing. For these women, oocyte cryopreservation allows them to maintain their reproductive lifespan until an age when they feel ready to become mothers.

L'augmentation de la survie des patientes atteintes de cancer et la tendance à retarder la première maternité sont deux phénomènes distincts menant à une hausse de la demande de préservation de fertilité. Actuellement, une préservation d'ovocytes est possible chez les patientes avec une exposition hormonale légère et sans retarder les traitements oncologiques. Ainsi, toute patiente recevant un diagnostic oncologique devrait être orientée vers un spécialiste de la fertilité. De plus, les indications de préservation de fertilité se sont élargies à de nombreuses pathologies bénignes. La conscientisation de la diminution de fertilité liée à l'âge, couplée à une tendance à retarder la première grossesse, pousse de plus en plus de femmes à faire appel à l'AGE Banking (Anticipation of Gamete Exhaustion), technique qui leur permet de maintenir leur potentiel reproductif jusqu'à l'âge où elles désireront devenir mères.

Anti-adhesion Gel versus No gel following Operative Hysteroscopy prior to Subsequent fertility Treatment or timed InterCourse (AGNOHSTIC), a randomised controlled trial: protocol.

STUDY QUESTIONS: Does the application of anti-adhesion gel, compared to no gel, following operative hysteroscopy to treat intrauterine pathology in women wishing to conceive increase the chance of conception leading to live birth? WHAT IS KNOWN ALREADY: Intrauterine adhesions (IUAs) following operative hysteroscopy may impair reproductive success in women of reproductive age. Anti-adhesion barrier gels may decrease the occurrence of IUAs, but the evidence on their effectiveness to improve reproductive outcomes is sparse and of low quality. STUDY DESIGN SIZE DURATION: This multicentre, parallel group, superiority, blinded and pragmatic randomised controlled trial is being carried out in seven participating centres in Belgium. Recruitment started in April 2019. Women will be randomly allocated to treatment with anti-adhesion gel (intervention group) or no gel (control group). Sterile ultrasound gel will be applied into the vagina as a mock-procedure in both treatment arms. The patient, fertility physician and gynaecologist performing the second-look hysteroscopy are unaware of the allocated treatment. Power analysis, based on a target improvement of 15% in conception leading to live birth using anti-adhesion gel, a power of 85%, a significance level of 5%, and a drop-out rate of 10%, yielded a number of 444 patients to be randomised. The baseline rate of conception leading to live birth in the control group is expected to be 45%. PARTICIPANTS/MATERIALS SETTING METHODS: Women of reproductive age (18-47 years), wishing to conceive (spontaneously or by fertility treatment) and scheduled for operative hysteroscopy to treat intrauterine pathology (endometrial polyps, myomas with uterine cavity deformation, uterine septa, IUAs or retained products of conception) are eligible for recruitment. Women may try to conceive from 3 to 6 weeks after receiving allocated treatment with follow-up ending at 30 weeks after treatment. If the woman fails to conceive within this timeframe, a second-look hysteroscopy will be scheduled within 2-6 weeks to check for IUAs. The primary endpoint is conception leading to live birth, measured at 30 weeks after randomisation. The secondary endpoints are time to conception, clinical pregnancy, miscarriage and ectopic pregnancy rates, measured at 30 weeks after receiving allocated treatment. The long-term follow-up starts when the patient is pregnant and she will be contacted every trimester. STUDY FUNDING/COMPETING INTERESTS: This work is funded by the Belgian Healthcare Knowledge Centre (KCE). The anti-adhesion gel is supplied at no cost by Nordic Pharma and without conditions. Dr. Tomassetti reports grants and non-financial support from Merck SA, non-financial support from Ferring SA, personal fees and non-financial support from Gedeon-Richter, outside the submitted work. None of the other authors have a conflict of interest.

Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease.

OBJECTIVE: We assessed the curative effect of a second curettage in patients with persistent hCG serum levels after first curettage for a gestational trophoblastic disease (GTD). STUDY DESIGN: This prospective observational study used the data of the Belgian register for GTD between July 2012 and January 2017. We analysed the data of patients who underwent a second curettage. We included 313 patients in the database. Primary endpoints were need for second curettage and chemotherapy. RESULTS: Thirty-seven patients of the study population (12 %) underwent a second curettage. 20 had persistent human chorionic gonadotropin hormone (hCG) elevation before second curettage. Of them, 9 patients (45 %) needed no further treatment afterwards. Eleven patients (55 %) needed further chemotherapy. Nine (82 %) were cured with single-agent chemotherapy and 2 patients (18 %) needed multi-agent chemotherapy. Of the 37 patients, patients with hCG levels below 5000 IU/L undergoing a second curettage were cured without chemotherapy in 65 % versus 45 % of patients with hCG level more than 5000 IU/L. Of the ten patients with a hCG level below 1000 IU/L, eight were cured without chemotherapy. CONCLUSIONS: Patients with post-mole gestational trophoblastic neoplasia can benefit from a second curettage to avoid chemotherapy, especially when the hCG level is lower than 5000 IU/L.

A European survey on treatment of hydrosalpinges in infertile women on behalf of the European Society for Gynaecological Endoscopy (ESGE) Special Interest Group (SIG) on Reproductive Surgery.

A questionnaire-based survey was conducted among members of the European Society for Gynaecological Endoscopy (ESGE), with the aim of increasing awareness of the diagnosis and surgical treatment of tubal disease as an alternative to in-vitro fertiliszation (IVF). Seventeen participants (34%) occasionally used a test for prediction of the ovarian reserve before surgery, and the most commonly used test was anti-mullerian hormone assay (39/50; (80%). Laparoscopy was the preferred method for staging tubal disease (43/50; 86%).Thirty-seven (76%) participants always performed salpingectomy or tubal occlusion before the first IVF attempt. Thirty (60%) of the gynaecological surgeons considered the outcome with tubal surgery and IVF to be similar in mild tubal disease, whereas for severe disease, 31/50 (62%) felt that surgery had worse outcome. Among other factors to be considered in choosing a strategy for treating infertility, 20/50 (40%) of respondents listed the stage of disease. The findings of this survey suggest that first-line treatment for women younger than 35 years old with minor tubal pathology, is tubal surgery. IVF appears to be offered if there are other infertility factors, if the patient is >38 years old and if moderate to severe tubal disease is present.

[Polycystic ovary syndrome : the advantages of multidisciplinary management]. / Le syndrome des ovaires micropolykystiques : l'avantage d'une prise en charge multidisciplinaire.

The polycystic ovary syndrome is one of the most frequent endocrine disorders in women of reproductive age. The first signs and symptoms of the disease may be present as early as puberty. Diagnostic criteria include hyperandrogenism (clinical or biological), ovulatory dysfunction and polycystic ovarian morphology on ultrasound. The consequences of the syndrome are multiple. These consist of fertility issues and metabolic anomalies with increased cardiovascular risk, but also sleep disturbances, increased risk of endometrial hyperplasia and endometrial cancer and a potentially important psychological impact with decreased quality of life. The management of polycystic ovary syndrome is multidisciplinary and treatment is variable, depending on symptoms and the patient's desire for fertility. In all cases, measures aiming to improve the metabolic dysfunction are essential, going from adopting a healthy lifestyle to adequate therapy of each metabolic anomaly.

Le syndrome des ovaires micropolykystiques est une des endocrinopathies les plus fréquentes de la femme en âge de reproduction. Les premiers signes et symptômes peuvent se manifester dès la puberté. Les critères de diagnostic reposent sur une hyperandrogénie (clinique ou biologique), une anovulation chronique et un aspect d'ovaires micropolykystiques à l'échographie. Les conséquences du syndrome sont multiples, essentiellement concernant les troubles de la fertilité et les perturbations métaboliques avec un risque cardio-vasculaire augmenté, mais également des anomalies du sommeil, un risque augmenté d'hyperplasie endométriale et de cancer endométrial et un impact psychologique parfois important avec diminution de la qualité de vie. La prise en charge est multi-disciplinaire et le traitement variable, en fonction des symptômes et des souhaits de fertilité de la patiente. Dans tous les cas, une prise en charge métabolique, avec une hygiène de vie saine et des traitements visant les perturbations métaboliques individuelles, est essentielle.

Use of methotrexate in the treatment of ectopic pregnancies: a retrospective single center study.

INTRODUCTION: The aim of this study was to evaluate the efficacy of methotrexate (MTX) in the treatment of ectopic pregnancies. We identified predictive factors of success or failure and compared our results with previous studies to make recommendations for its use. MATERIAL AND METHODS: A cohort of 61 patients from a single center was retrospectively analyzed. Inclusion criteria were a diagnosis of ectopic pregnancy and treatment with a single-dose injection of MTX. The need to perform surgery despite MTX was defined as treatment failure while needing a second MTX injection was not. RESULTS: In our cohort, MTX demonstrated a success rate of 80%. This rate rose to 84% when patients with human Chorionic Gonadotropin (hCG ) > 5,000 IU/L were excluded. Twenty percent underwent surgery for pain, increased mass size and/or suboptimal hCG kinetics. Low hCG levels on days 0, 4 and 7 as well as the absence of pain, metrorrhagia and hemoperitoneum were predictive of success. MTX was also efficient in the treatment of persisting pregnancies of unknown location (PUL). CONCLUSION: Our results are consistent with previous studies and emphasize the fact that MTX is less effective above a certain level of hCG. We obtained a cut-off value of 2439 IU/L with a sensitivity of 66.7% and a specificity of 93.9%. MTX should not be used when hCG is higher than 5,000 IU/L and laparoscopic surgery should be performed. Our results bring additional data about the efficacy of MTX in the management of persisting pregnancies of unknown location.

Clinical performance of a specific granulocyte colony stimulating factor ELISA to determine its concentration in follicular fluid as a predictor of implantation success during in vitro fertilization.

This study aimed to demonstrate the clinical performance of an ultra-sensitive follicular fluid (FF) granulocyte colony stimulating factor (G-CSF) immunoassay to confirm previous work, indicating a correlation between FF G-CSF concentration and live birth potential of the corresponding embryo after in vitro fertilization. This study was a noninterventional, prospective, diagnostic clinical multicentric study conducted between August 2012 and January 2014 with 396 single embryo transfers (SETs) from 278 subjects. During oocyte retrieval, FF was individually collected. Embryo morphology and implantation success were evaluated. The implantation success rate in the high G-CSF group (32.3%) was higher than the overall rate (27.5%). Similarly, for embryos with optimal morphology, implantation success rates were highest among those in the high G-CSF concentration category (34.5%) compared with low (19.6%) and intermediate (29.8%) G-CSF concentration categories. Significant differences in mean G-CSF concentrations were observed between the study sites. To minimize bias, analyses were repeated using data from the center with the largest number of SETs. In alignment with the overall analysis, this center demonstrated a 43% greater probability of implantation for optimal embryos with high G-CSF compared to the general implantation rate among optimal embryos and a 327% increase compared with the implantation rate of optimal embryos with low G-CSF.

[Impact of thyroid function on the result of intrauterine insemination among fertile women]. / Impact de la fonction thyroïdienne sur le résultat des inséminations artificielles avec sperme de donneur chez des femmes fertiles.

This retrospective study compares the impact of TSH level on the result of intrauterine insemination (IUI) with donor sperm in fertile women. There is no difference in women characteristics and their fertility. Despite the fact that the thyroid hormones influence fertility, this study shows that TSH before IUI doesn't influence pregnancy and live birth rates. However, thyroid hormones are important for the foetal brain development and pregnancy. Therefore, it is important to evaluate the thyroid function and prescribe a treatment if needed, (if TSH superior to 2.5 mUI/l) as the pregnancy is a stressful factor for thyroid and an infraclinical hypothyroidism can evolve into a clinical hypothyroidism in pregnant women.

Cette étude rétrospective, incluant 526 patientes, s'intéresse à l'effet de la fonction thyroïdienne sur le résultat des inséminations artificielles avec sperme de donneur chez des patientes a priori fertiles. Il n'existe aucune différence significative dans les caractéristiques des patientes et leur bilan de fertilité. Bien que la fertilité soit influencée par la fonction thyroïdienne, cette étude montre que les taux de grossesse et de naissance obtenus ne sont pas influencés par le taux de TSH dosé avant le début des inséminations. Toutefois, les hormones thyroïdiennes jouent un rôle dans le bon déroulement de la grossesse et le développement cérébral fœtal. Il est donc important d'évaluer la fonction thyroïdienne en début de grossesse et d'instaurer un traitement substitutif si nécessaire (si TSH sup�rieur a 2,5 mUI/l). En effet, la grossesse est considérée comme un stress pour la thyroïde et une fonction thyroïdienne limite avant la grossesse peut décompenser pendant celle-ci.

[Do we need to perform systematic supracervical hysterectomy during laparoscopic sacrocolpopexy?] / Doit-on réaliser systématiquement une hystérectomie subtotale dans le cadre d'une promontofixation cœlioscopique ?

OBJECTIVE: To evaluate the place of subtotal hysterectomy during laparoscopic sacrocolpopexy. METHODS: This retrospective observational study includes patients undergoing laparoscopic sacrocolpopexy between November 2010 and March 2015 at the Centre Hospitalier Régional de la Citadelle, Liège, Belgium. Patient characteristics, medical and surgical history were collected. Clinical data, operative and intraoperative complications were analyzed. The postoperative results were collected at 6 weeks, 4 months and then every year with a clinical and anatomical evaluation by POP-Q (Pelvic Organ Prolapse - Quantification). RESULTS: Ninety-four patients were included in the study. Sixty-four patients (68.1%) underwent sacrocolpopexy with subtotal hysterectomy, 12 patients (12.7%) had sacrocolpopexy with uterine preservation, 16 patients (17%) had a clinical history of hysterectomy and 2 patients (2.2%) have had sacrocolpopexy with total hysterectomy. The mean age of the patients was 61±20 years, parity 2±2 and BMI 25.2±7.32. The objective success rate, defined by a stage of POP-Q<2, was 93.75% in the sacrocolpopexy group with subtotal hysterectomy vs. 66.7% in the sacrocolpopexy group with uterine preservation (P=0.019). The subjective success rates were 98.4% and 83% respectively (P=0.063ns). CONCLUSION: Sacrocolpopexy offers good anatomical results, with better objective and subjective success rates when associated with a subtotal hysterectomy. The decision of hysterectomy should consider the risk/benefit balance and the patient's preferences.

[Asherman's syndrome : management after curettage following a postnatal placental retention and literature review]. / Syndrome d'Asherman. Prise en charge après curetage suite à une rétention placentaire post-natale et revue de la littérature.

Asherman's syndrome (AS) is a partial or complete obliteration of the uterine cavity after intrauterine trauma. Approximately 90 % of severe AS cases occur after abortion curettage or postpartum curettage. Clinical signs and symptoms are abnormalities of the cycle (hypomenorrhoea or amenorrhoea) and fertility disorders. We have reviewed the recent literature on AS following the description of a typical clinical case. The management of AS is not easy. It must be done by experienced surgeons. Realization of several surgeries is sometimes mandatory, with the use of anti-adhesive devices between interventions. Its complex management encourages insistence on the avoidance of its risk factors.

Le syndrome d'Asherman (SA) correspond à une oblitération plus ou moins complète de la cavité utérine et se développe après un traumatisme intra-utérin. Approximativement 90 % des cas de SA sévères surviennent après un curetage post-abortum ou post-partum. Il se manifeste par des anomalies du cycle (hypoménorrhée ou ménorrhée) et des troubles de la fertilité. Nous avons revu la littérature récente concernant le SA à la suite de la description d'un cas clinique exemplatif. La prise en charge du SA n'est pas aisée : elle doit se faire par les chirurgiens expérimentés et passe parfois par la réalisation de plusieurs chirurgies, avec l'utilisation des dispositifs anti-adhésifs entre les interventions. Sa prise en charge complexe incite à insister sur l'éviction des facteurs favorisant sa survenue.

[Chemical peritonitis complicating the spontaneous rupture of a dermoid cyst of the ovary]. / Péritonite chimique compliquant la rupture spontanée d'un kyste dermoïde de l'ovaire.

Mature ovarian teratoma is the most frequent benign tumor in premenopausal women. It is usually asymptomatic but complications are possible such as adnexal torsion, infection, malignant transformation or cystic rupture. The latter can be spontaneous or more often occurs during surgery of excision of dermoid cyst. It can rarely result in chemical peritonitis, which is due to the irritation of the peritoneal serosa by the aseptic content of the tumour. We report the case of a patient who undrewent an emergency laparotomy for a chemical peritonitis following a spontaneous rupture of a dermoid cyst. Afterwards, she developed an acute respiratory distress syndrome that required an admission in the intensive care unit and subsequent surgery.

Le tératome mature de l'ovaire est la tumeur ovarienne bénigne la plus fréquente chez la femme en pré-ménopause. Le plus souvent, il est asymptomatique, mais il peut se compliquer par une torsion annexielle, une infection, une dégénérescence maligne ou une rupture kystique. Celle-ci peut être spontanée ou, plus souvent, survenir lors d'une chirurgie d'exérèse du kyste. Rarement, elle peut entraîner une péritonite chimique. Celle-ci est consécutive à l'irritation de la séreuse péritonéale par le contenu aseptique da la tumeur. Nous rapportons ici le cas d'une patiente opérée en urgence pour une péritonite chimique suite à une rupture spontanée d'un kyste dermoïde. Dans les suites opératoires, la patiente a développé un syndrome de détresse respiratoire aigu qui a nécessité une prise en charge aux soins intensifs et une nouvelle intervention chirurgicale.

A self-administered questionnaire to measure the painful symptoms of endometriosis: Results of a modified DELPHI survey of patients and physicians.

PURPOSE: To develop a questionnaire based on patients' verbal descriptors, to measure the painful symptoms of endometriosis. METHODS: We performed a two-round modified DELPHI procedure mixing endometriosis patients and physicians to select a set of statements to describe the painful symptoms of endometriosis. Each panelist rated each statement based on diagnosis validity and clarity. The clinicians were experts in endometriosis management selected from various geographic regions in France. Patients were women with surgically confirmed endometriosis who volunteered from a patient association and from the recruitment of the participating physicians. The first round questions were derived from words and phrases in narratives of pain by endometriosis patients. RESULTS: Overall, 76 experts were invited, and of these 56 (74%), comprising 33 patients and 23 gynecologists, responded to the first round questionnaire, and 40 (71.4%) to the second round. Among the 48 statements assessed in the first-round questionnaire, 11 were selected after completion of the two round DELPHI procedure. After discussion and rewording of some items, a total of 21 questions were selected during a final face-to-face meeting. The content of the final questionnaire is organized according to four dimensions: (i) spontaneous pelvic pain and dysmenorrhea, (ii) dyspareunia, (iii) painful bowel symptoms, (iv) and other symptoms. We also provide an English (UK) version produced using several steps of translation and back-translation. CONCLUSIONS: The questionnaire has content validity to measure the subjective experiences of patients with painful endometriosis and can provide a solid basis on which to develop an efficient patient-centered outcome to measure the painful symptoms in therapeutic or in diagnostic studies of endometriosis.

[Use of sFlt-1/PlGF ratio in preeclampsia : a monocentric retrospective analysis]. / L'utilisation du ratio sFlt-1/PlGF dans la prééclampsie : une analyse rétrospective monocentrique.

Soluble Fms-like tyrosine kinase 1 (sFlt-1) is an anti-angiogenic factor released in higher amounts in preeclampsia and implicated in endothelial dysfunction. sFlt-1/PlGF ratio is used in the prediction of preeclampsia. An sFlt-1/PlGF ratio inferior to 38 predicts the short-term absence of preeclampsia. A ratio ? 85 (early-onset PE) or ? 110 (late-onset of PE) could diagnose preeclampsia. In this study, sFlt-1/PlGF ratio has been measured in 183 patients. Sixty-seven preeclampsia have been diagnosed preeclamptic at delivery. The median sFlt-1/PlGF ratio was 100.3. The median ratio among women with preeclampsia (N=67) versus no preeclampsia (N=116) was 212.7 versus 35.4. In accordance with this analysis, an sFlt-1/PlGF ratio ? 38 has a sensibility of 95,5 % and a specificity of 73.3 %. The positive predictive value and the negative predictive value were 67.4 % and 96.6 %, respectively. These results suggest that sFlt-1/PlGF ratio is helpful in the diagnosis of preeclampsia.

La Fms-like tyrosine kinase 1 soluble (sFlt-1) est un facteur anti-angiogénique libéré en quantité excessive dans la prééclampsie (PE) et impliqué dans la dysfonction endothéliale. Il est comparé au facteur de croissance placentaire pro-angiogénique (PlGF) qui diminue dans la PE. Le ratio sFlt-1/PlGF est présenté dans la littérature comme outil dans la prédiction de la prééclampsie. Un ratio inf�rieur a 38 confirme l'absence de prééclampsie à court terme. Un ratio ? 85 dans la PE précoce (avant 34 semaines d'aménorrhée (SA)) et ? 110 dans la PE tardive (après 34 SA) peut poser le diagnostic de prééclampsie. Dans cette étude rétrospective monocentrique, le ratio sFlt-1/PlGF a été dosé chez 183 patientes à risque de PE dont 67 ont présenté une prééclampsie. Le ratio sFlt-1/PlGF médian pour toutes les patientes évaluées est 100,3. Le ratio médian pour les patientes ayant déclaré une prééclampsie (N=67) est 212,7 alors que celui des femmes sans prééclampsie (N=116) est de 35,4. En accord avec ces analyses, un ratio sFlt-1/PlGF ? 38 possède une sensibilité égale à 95,5 % et une spécificité égale à 73,3 % dans la mise au point de la PE. Les valeurs prédictives positive (VPP) et négative (VPN) sont, respectivement, 67,4 % et 96,6 %. Ces résultats suggèrent que le ratio sFlt-1/PlGF peut être une aide dans le diagnostic de la prééclampsie.